Introduction: Social dysfunction is a common symptom of several neuropsychiatric disorders. However, only in the last few years research began to systematically investigate clinical aspects of this relevant outcome. Interestingly, its distribution and link with other clinical variables is still unclear. This study investigated social dysfunction in 4 different cohorts of patients affected by mood disorders and schizophrenia to evaluate 1) the degree of social dysfunction in these populations; 2) the associations among social dysfunction and socio-demographic and psychopathological features. Methods: Data from 4 independent studies (CATIE, GSRD ES1, ES2 and ES3, STAR*D, STEP-BD) were investigated. Behavioural and affective indicators of social dysfunction were derived and operationalized from scales or questionnaire items related to the interaction with relatives, friends and significant people in patients affected by schizophrenia (N=765) and mood disorders (N=2278+1954+1829). In particular the social dysfunction indicator was derived from Sheehan Disability Scale (SDS) for GSRD sample, from the Work and Social Adjustment Scale (WSAS) for STAR*D sample, from the Life-Range of Impaired Functioning Tool (LRIFT) for STEP-BD sample, and from the Quality of Life Scale (QOLS) for CATIE sample. The distribution of social dysfunction was described and association with socio-demographic and psychopathological characteristics were analysed. Results: Social dysfunction indicators showed a broad distribution in all samples investigated. Consistently across studies, social dysfunction was associated with higher psychopathological severity (all samples except CATIE) and suicide risk (GSRD ES1 and ES2, STAR*D, and STEP-BD) that explain up to 47% of the variance, but also to lower education level (GSRD ES2, STAR*D, CATIE, and STEP-BD), poorer professional/work status (GSRD ES2 and ES3, STAR*D, CATIE, and STEP-BD), marital status (STAR*D and CATIE), age (younger age in GSRD ES1 and STAR*D, older age in CATIE), higher BMI (GSRD ES2 and ES3, and STEP-BD), and smoking (GSRD ES2 and ES3). Conclusion: Our results demonstrated that a significant percentage of patients affected by both mood disorders and schizophrenia shows relevant social dysfunction. Social dysfunction is related, but not completely explained by psychopathological severity. In several patients, it tends to persist also during remission state. Socio-demographic and lifestyle factors were also found to play a role and should therefore be taken into consideration in further studies investigating social dysfunction.
Introduction
the STAR*D, the STEP-BD, and the CATIE studies) and in three European MDD samples, which provided an overall assessment of socio-demographic and psychopathological features (i.e. the GSRD samples) (see methods section for detail).
Methods

Samples investigated
GSRD sample
The GSRD sample comprised three different subsamples, which were collected thanks to the European Group for the Study of Resistant Depression (GSRD) (31). For all three original samples ethical approval was obtained from local research ethics committees.
European subsample 1 (ES1)
The study design and population have been described elsewhere (32) . In brief, in this crosssectional study, recruitment of patients was performed from January 2000 until February 2004, based on consecutive ascertainment of depressed inpatients and outpatients in the specialist referral centers involved in the study. Inclusion criteria were 1) meeting criteria for a diagnosis of MDD according to DSM-IV criteria; 2) at least one adequate antidepressant trial received during the current or most recent depressive episode. Socio-demographic features were collected through a specific form at the inclusion. A 17-item Hamilton Rating Scale for Depression (HAMD-17) (33) score was obtained for each patient at inclusion. For 552 patients, the Sheehan Disability Scale (SDS) (23) was obtained as well. For the aim of the present study, only subjects with available SDS were considered.
European subsample 2 (ES2)
388 MDD patients were recruited in the context of a subsequent European multicenter project, lead by the GSRD as well, from January 2005 to December 2011. Inclusion and exclusion criteria have been previously described in detail (34) . In brief, patients met DSM-IV TR criteria for a major depressive episode defined as moderate or severe as assessed by the Montgomery and Asberg Depression Rating Scale (MADRS) total score at baseline > 22 (35) . Patients entered a two-stage trial after the failure of at least one adequate antidepressant treatment (retrospectively assessed), firstly receiving a 6-week venlafaxine treatment and then, in case of non-response, a 6-week escitalopram treatment. Depressive symptoms were evaluated by MADRS and HAMD-21 at baseline and biweekly until week 12. Socio-demographic features were collected at inclusion through a specific form. The SDS was administered at inclusion as well (23). For the aim of the present study, only data at baseline were considered. Related Phenotype (TRD3)" by the GSRD. Study design and study population were described elsewhere (36) . Briefly, in this cross-sectional study subjects, aged 18 years and older who met the DSM-IV TR criteria for MDD were recruited by the specialist referral centers involved in the study. Subjects must have had at least one adequate previous antidepressant treatment for the current episode. The patients' socio-demographic, psychosocial, and clinical information were gathered within a detailed clinical interview conducted by specifically trained psychiatrists and specific questionnaires, including SDS (cross-sectional data collection process (36) ). For the aim of the present study, only subjects with available SDS were considered (n=1338).
STAR*D sample
The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study was performed to compare the efficacy and tolerability of various antidepressant therapies through four sequential treatment levels. Descriptions of the study design and study population are detailed elsewhere (37) . Briefly, non-psychotic MDD (DSM-IV criteria) patients were enrolled from primary care or psychiatric outpatient clinics. Severity of depression was assessed using the 16-item Quick Inventory of Depressive Symptomatology-Clinician Rated (QIDS-C) (38) at baseline, weeks 2, 4, 6, 9, and 12. At baseline, psychopathological, clinical and demographic information were collected. Furthermore, a detailed assessment of global functioning was performed (for a detailed description see (39)), throughout the administration of the 12-item short form health survey (SF-12) (40), the Work and Social Adjustment Scale (WSAS) (25) , and the 16-item Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (41). All patients received citalopram in level 1. As depressive symptoms and global functioning were rated in level 1, for the aim of the present study only this level was considered.
STEP-BD sample
The Systematic Treatment Enhancement Program for Bipolar disorder (STEP-BD) study is one of the largest clinical prospective trial including bipolar patients to date (42). STEP-BD was a prospective study, performed to develop and expand knowledge on the management and treatment of BD and evaluate the longitudinal outcome of the disease. STEP-BD applied a hybrid design to collect longitudinal data as patients make transitions between naturalistic studies and randomized clinical trials (42). Description of the study design and study population are detailed elsewhere (42, 43) . In brief, patients older than 15 years of age, affected by bipolar disorder type I or II, cyclothymia, bipolar disorder NOS, or schizoaffective disorder, bipolar subtype were re cruited. Exclusion criteria are minimal, and include unwillingness or inability to comply with study assessments, inability to give informed consent, or need for inpatient detoxification at the time of enrolment (42). For the aim of the present study, only data at the entry were considered.
CATIE sample
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study is a large, 18-month, National Institute of Mental Health-funded, randomized controlled trial designed to compare the outcome of 1 conventional antipsychotic medication and 4 second-generation antipsychotic medications. The study baseline visit occurred within 21 days of the screening visit.
Eligible participants were initially randomized to olanzapine, risperidone, ziprasidone, quetiapine, or perphenazine under double-blind conditions and received treatments for up to 18 months or until treatment was discontinued for any reason. At baseline, the patients' socio-demographic, psychosocial, and clinical information were gathered throughout a detailed assessment, including the Quality of Life Scale (QOLS) (44) (for detail see (45) ). More information about the study design and study population can be found elsewhere (46) . For the aim of the present study, only baseline data were considered.
Indicators of social dysfunction
Social dysfunction is a common symptom of several neuropsychiatric disorders. However, only very recently systematic evaluations of social functioning were implemented, the most part of studies performed so far lacking any specific assessments. Consistently, specific measures of social dysfunction were also missing in the datasets investigated in the present study. Therefore, different indicators of social dysfunction were derived and operationalized for each dataset from available clinical scale and demographic information after a careful evaluation performed by three researchers (S.P., E.M.P and A.S.). The evaluation was based on the selections of the available items that specifically assessed social interactions with relatives, friends and other significant people. Conversely, the items focusing on work/school functioning were excluded because it has been hypothesized that the two functions are characterised by different motivational drivers (47) (48) (49) . When possible, the same indicator was selected from the different datasets in order to increase as much as possible comparability across the different populations. Each social dysfunction indicator was standardized accordingly with the following formula (original value -mean / SD) and used as main outcome of interest.
GSRD sample
For all the three subsamples included in GSRD sample, the SDS was available (23). The SDS is a self-report scale which assesses on a ten-point scale how much the symptoms have disrupted 1) patient's work/school work; 2) patient's social life/leisure activities; and 3) patient's family life/home responsibilities. According to the developers' instructions, the three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). Patients who score 5 on any of the three scales likely have a significant functional impairment. For the aim of the present study, we combined the scores of item 2 and item 3 into an unique measure of social dysfunction, ranging from 0 (unimpaired) to 20 points (highly impaired).
STAR*D sample
For the STAR*D sample, the WSAS (25) was identified as the most informative scale to derive an operationalized indicator of social dysfunction. WSAS is a self-report scale which assesses on an eight-point scale 5 items investigating the patient's ability to do certain day-to-day tasks in his or her life. For the aim of the present study, we combined the scores of item 3 ("Social activities impaired: Because of my depression, my social leisure activities (with other people, such as parties, bars, clubs, outings, visits, dating, home entertainment) are impaired") and item 5 ("Close J o u r n a l P r e -p r o o f relationships impaired: Because of my depression, my ability to form and maintain close relationships with others, including those I live with is impaired") into an unique measure of social dysfunction, ranging from 0 (unimpaired) to 16 points (highly impaired).
STEP-BD sample
For the STEP-BD sample, the Life-Range of Impaired Functioning Tool (LRIFT) (50) was selected as the most informative scale to derive and operationalize an indicator of social dysfunction. The LRIFT was specifically developed to assess functional impairment in different areas, such as work, interpersonal relations, satisfaction, and recreation. LRIFT is a clinical administrated scale which assesses on a five-point scale (in the version modified for the STEP-BD study) functional impairment. For the aim of the present study, we combined the scores of item 2c ("Interpersonal relations with other relatives") and item 2d ("Interpersonal relations with friends") into a unique measure of social dysfunction, ranging from 2 (unimpaired) to 10 points (highly impaired).
CATIE sample
For the CATIE sample, the Quality of Life Scale (QOLS) -"Interpersonal relations" category (44) was selected as indicator of social dysfunction. The QOLS is a 21-item scale, ranging from 0 (highest impairment) to 6 (almost normal), which was developed to assess deficit symptoms in schizophrenia. The category "Interpersonal relations" (items 2-8) assesses various aspects of interpersonal and social experience, although many items go beyond rating amount of frequency of social contact to such complex judgment as capacity for intimacy, active versus passive participation, and withdrawal tendencies (44) . This implies a greater risk of bias due to the subjective nature of the assessment compared to other scales. For the purpose of this study, we used as social dysfunction indicator the mean of the 9 items of the QOLS "Interpersonal relations" category, as suggested by previous studies (51), ranging from 0 (unimpaired) to 6 (highly impaired).
For the present study, only subjects with available data about social functioning were considered. These data were available for 2278 MDD patients in the GSRD sample, for 1954 MDD patients in the STAR*D sample, for 765 SCZ patients in the CATIE sample, and for 1829 BD patients in the STEP-BD sample. Thus, overall, we included for analysis 6826 subjects affected by MDD, BD, and SCZ.
Statistical analysis
Socio-demographic and clinical characteristics were described using chi-square statistics for categorical variables and analysis of variance (ANOVA) for continuous variables. In order to investigate the associations with social dysfunction indicators, simple regressions were used for continuous variables and ANOVA for categorical variables. Further, bivariate associations of social dysfunction indicators with socio-demographic and clinical features adjusted for psychopathology severity (i.e., HAMD, MADRS or PANSS total scores) were investigated through multiple linear regressions or analyses of covariance (ANCOVAS). These analyses were performed in the total samples and in the remitted/less severe subsamples. Remitted subsamples were available for GSRD ES1 and ES2 samples (remission has been defined as to have HAMD-21 score lower than 13, i.e. absence of major depressive episode (33)), for STEP-BD sample (remission has been defined as to J o u r n a l P r e -p r o o f have MADRS score lower than 7 and MRS score lower than 15, i.e. absence of both major depressive episode and manic/mixed episode (35, 52) ), and for CATIE sample (remission defined as PANSS score lower than 60, i.e. absence of clinical relevant symptoms (53)). For GSRD ES2 and STAR*D samples remitted patients were not available. Thus, we decided to perform an exploratory analysis on the less-severe patients subsamples, defined as to have HAMD-17 score lower than 19 for both samples (i.e. patients with a moderate depressive episode (33) ). Finally, multiple linear regression analyses were also conducted to investigate the variance explained of social dysfunction indicators by continuous and categorical variables. All p values were 2-tailed and statistical significance was set at the standard level of p=0.05. Statistical analyses were conducted using STATISTICA software package (StatSoft, Inc. Tulsa, OK, USA).
Results
Descriptive analysis of social dysfunction indicators across different samples
Socio-demographic and psychopathological features of the samples under investigation were described elsewhere (32, 34, 36, (54) (55) (56) and shown in Supplementary Table 1 .
Social Dysfunction Indicators Distribution by psychopathology severity
The distributions of social dysfunction indicators in each sample are showed in Figure 1 . For each dataset, we showed the distribution in the total sample, in the sub-sample of less-severe patients, and in the sub-sample of remitted patients (see Figure 1 ). Of note, as previously stated, for GSRD ES2 and STAR*D samples, remitted patients (i.e. the sub-sample of patients who achieved symptomatology remission, as detailed below) were not available. As expected, in all mood disorder samples, social dysfunction indicators showed more impairment in non-remitted patients as compared to less severe and to remitted patients (all p<0.001, data not shown). Counter-intuitively, in SCZ sample (CATIE) social dysfunction indicators showed more impairment in remitted patients as compared to non-remitted patients (p<0.001).
Furthermore, the percentage of patients with severe social dysfunction was different across the diagnostic groups. In particular, in the ES1 sample (MDD) patients with severe social dysfunction were 313 (65.07%) in the total sample and 66 (41.51%) in the remitted subsample; in the ES2 sample (MDD) patients with severe social dysfunction were 233 (60.05%) in the total sample and indicators were associated with psychopathological severity (all p<0.001), as measured by the available psychometric scales. Therefore, we repeated the analyses 1) adding the psychopathological severity score as covariate and 2) in the remitted/less severe patients only (defined by the scores at psychometric scales, as detailed below) in each dataset. Finally, we performed various multiple linear regression analyses to investigate the variance explained of social dysfunction indicators by the identified predictors in each dataset.
Here below, the associations found in these analyses were detailed for each sample (a summary of the associations found is showed in Table 2 and detailed in Supplementary Table 2 ).
GSRD sample ES1 sub-sample
In the ES1 sub-sample, higher social dysfunction (SDS Item 2 + Item 3) was associated with higher HAMD-21 total score (p<0.001), younger age (p=0.02), higher suicide risk (p<0.001), anxiety disorder co-morbidity (p<0.001), benzodiazepines co-treatment (p=0.009), and antipsychotic drug augmentation (p=0.03).
Adjusting for HAMD-21 total score, social dysfunction was still associated with higher suicide risk (p=0.02) and antipsychotic drug augmentation (p=0.04). Considering together HAMD-21 total score and age in a multiple regression analysis, younger age was still associated with social dysfunction (p=0.02).
In the remitted patients of the ES1 sub-sample (i.e., patients with HAMD-21 < 13), social dysfunction was associated with higher HAMD-21 total score (p=0.002), younger age (p=0.04), higher suicide risk (p=0.005), and anxiety disorder co-morbidity (p=0.008).
In ES1 sub-sample, the best fitting model included the variables HAMD-21 total score, age, suicide risk, benzodiazepines co-treatment, and antipsychotic drug augmentation. It explained the 23% of the variance of social dysfunction indicator (F=22.65, df=6, p<0.001).
ES2 sub-sample
In the ES2 sub-sample, social dysfunction (SDS Item 2 + Item 3) was associated with higher HAMD-21 total score (p<0.001), lower educational level (p<0.001), lower income (p=0.002), poorer professional work (p<0.001), poorer professional status (p<0.001), presence of melancholic features of depressive episode (p<0.001), higher suicide risk (p=0.046), smoke habit (p=0.002), and higher BMI (p=0.035).
Adjusting for HAMD-21 total score, social dysfunction was still associated with lower educational level (p<0.001), lower income (p=0.006), poorer professional work (p<0.001), poorer professional status (p=0.006), and smoke habit (p=0.002). Considering together HAMD-21 total score and BMI in a multiple regression analysis, higher BMI was still associated with the social dysfunction (p=0.09).
In patients with moderate severity of the ES2 sub-sample (i.e., patients with HAMD-17 < 19), social dysfunction was associated only with the presence of melancholic features of depressive episode (p<0.001).
J o u r n a l P r e -p r o o f
In the ES2 sub-sample, the best fitting model included the variables HAMD-21 total score, educational level, main source of income, smoke habit, suicide risk, and BMI. It explained the 47% of the variance of social dysfunction indicator (F=1.64, df=101, p=0.002).
ES3 sub-sample
In the ES3 sub-sample, social dysfunction (SDS Item 2 + Item 3) was associated with higher HAMD-21 total score (p<0.001), lower income (p=0.017), poorer professional work (p=0.005), benzodiazepines co-treatment (p<0.001), antipsychotic drug augmentation (p<0.001), smoke habit (p=0.001), and higher BMI (p<0.001).
Adjusting for HAMD-21 total score, social dysfunction was still associated with poorer professional work (p<0.001), benzodiazepines co-treatment (p<0.001), antipsychotic drug augmentation (p<0.001), and smoke habit (p=0.001). Considering together HAMD-21 total score and BMI in a multiple regression analysis, higher BMI was still associated with social dysfunction (p<0.001).
In the remitted patients of the ES3 sub-sample (i.e., patients with HAMD-21 < 13), social dysfunction was associated with higher HAMD21 total score (p<0.001), lower income (p=0.044), poorer professional work (p=0.019), benzodiazepines co-treatment (p=0.04), antipsychotic drug augmentation (p=0.013), and higher BMI (p=0.003).
In the ES3 sub-sample, the best fitting model included the variables HAMD-21 total score, main source of income, smoke habit, benzodiazepines co-treatment, antipsychotic drug augmentation, and BMI. It explained the 34% of the variance of social dysfunction indicator (F=7.73, df=54, p<0.001).
STAR*D sample
In the STAR*D sample, social dysfunction (WSAS Item 3 + Item 5) was associated with higher HAMD-17 total score (p<0.001), younger age (p=0.004), lower education (yrs) and educational degree (p=0.004 and p=0.02, respectively), marital status (Cohabitant/ Married patients showed lower social dysfunction) (p<0.001), poorer professional status (p<0.001), and higher suicide risk (p<0.001).
Adjusting for HAMD-17 total score, social dysfunction was still associated with marital status (p<0.001), poorer professional status (p<0.001), and higher suicide risk (p<0.001). Considering together HAMD-17 total score and age in a multiple regression analysis, younger age was still associated with social dysfunction (p<0.001).
In the sub-sample of patients with moderate severity (i.e., patients with HAMD-17 < 19), social dysfunction was associated with higher HAMD-17 total score (p<0.001), marital status (p=0.009), and higher suicide risk (p=0.008).
In the STEP-BD sample, social dysfunction (LRIFT Item 2c + Item 2d) was associated with higher MADRS total score (p<0.001) and higher Mania Rating Scale (MRS) (52) total score (p<0.001), lower educational degree (p<0.001), poorer professional status (p<0.001), higher suicide risk (p<0.001), higher BMI (p<0.001), and medical co-morbidities (p=0.026).
Adjusting for MADRS total score, social dysfunction was still associated with lower educational degree (p=0.003), poorer professional status (p=0.007), and medical co-morbidities (p=0.002). Considering together MADRS total score and BMI in a multiple regression analysis, higher BMI was still associated with social dysfunction (p<0.001).
In the remitted sub-sample (i.e., patients with MADRS < 7 and MRS < 15), social dysfunction was associated with higher MADRS total score (p<0.001), lower educational degree (p<0.001), poorer professional status (p=0.026), and smoking habit (p=0.001).
In the STEP-BD, the best fitting model included the variables MADRS total score, MRS total score, BMI, medical co-morbidities, smoke habit, suicide risk, educational degree, and professional status. It explained the 24% of the variance of social dysfunction indicator (F=2.17, df=158, p<0.001).
CATIE sample
In the CATIE sample, social dysfunction (mean of the QOLS items 2-9 "Interpersonal relations" category) was associated with higher PANSS total score (p<0.001), older age (p=0.008), lower education (p<0.001), unemployment (p<0.001), and marital status (Cohabitant/Married patients showed lower social dysfunction) (p<0.001). Adjusting for PANSS total score, the associations with social dysfunction were confirmed (unemployment, p=0.002; marital status, p<0.001). Considering together PANSS total score and both age and education years in a multiple regression analysis, older age and lower education were still associated with social dysfunction (respectively, p=0.002 and p=0.001).
In the remitted sub-sample (i.e., patients with PANSS < 60), social dysfunction was associated with lower education (yrs) (p=0.01), marital status (Cohabitant/Married patients showed lower social dysfunction) (p=0.004), and unemployment (p=0.01).
In the CATIE sample, the best fitting model included the variables PANSS total score, marital status, education years, age, and professional work. It explained the 19% of the variance of social dysfunction indicator (F=15.79, df=11, p<0.001).
Discussion
In the present study social dysfunction indicators reflecting interactions with relatives, friends and other significant people showed a broad distribution in all the samples investigated, ranging from absence to severe social dysfunction (see Figure 1 ). This result is consistent with literature data (9, 21, 57) and suggests social dysfunction as a partially independent trans-diagnostic domain (3, 18) . Furthermore, when we repeated the analysis in the remitted or in less severe patient sub-samples in each dataset, we found that the percentage of mood disorder patients with severe social dysfunction was lower compared to the whole samples, but not absent. Counter-intuitively, in the SCZ sample, J o u r n a l P r e -p r o o f we found an higher percentage of patients with severe social dysfunction in the remitted sample, compared to the whole one. This result suggests that social dysfunction depends on psychiatric symptom severity; however, since in several cases severe social dysfunction persisted also in the remission state, particularly in SCZ, social dysfunction may have other drivers. Consistent with our results, a wide range of social dysfunction and persistence during remission were reported in patients with MDD, BD (9, 58, 59) and SCZ (57, 60) . Of note, the criteria used for identify the remitted sub-sample in SCZ (i.e. PANSS total score < 60) may be questionable (e.g. (61)), since it likely identify patients with residual predominant negative symptoms, rather than remitted one, partially justifying our counter-intuitively result.
Further, the percentage of patients with severe social dysfunction was different across the diagnostic groups. This percentage was lower in SCZ and in BD patients compared to MDD patients. Interestingly, this finding is opposite to literature data which show how SCZ and BD patients have often more severe social dysfunction compared to MDD patients (62, 63) . This inconsistency may be due to the self-report nature of some instruments we used to derive the social dysfunction indicators. Indeed, these instruments may caught the subjective experience of social dysfunction (i.e. loneliness, perceived social support, etc.) rather than objective aspects of social dysfunction (e.g. social network size, social cognition assessed with tasks, etc.) (see for example (3, 20) ). More severe social dysfunction scores based on subjective experience have been observed to a greater extent in MDD than in SCZ and BD (9, 64-66), partially supporting our findings. Furthermore, the QOLS "Interpersonal relations" category (items 2-9) -used to assess social dysfunction in the CATIE sample -included many items which go beyond rating amount of frequency of social contact to such complex judgment as capacity for intimacy, active versus passive participation, and withdrawal tendencies (44) . This implies a greater risk of bias due to the subjective nature of the assessment compared to other scales. Furthermore, raters may involuntary assess these aspects of social dysfunction comparing patients to SCZ population, rather than with the normal population, partially justifying the low rate of high social dysfunction found in the sample.
When considering the associations among social dysfunction indicators and socio-demographic factors, we observed some interesting associations.
First, in four independent datasets higher educational level was associated with lower social dysfunction. This association persists also when weighting for psychopathological severity in three datasets (STEP-BD, CATIE and ES2) and it was found also in remitted patients in STEP-BD and CATIE (Table 2) . Although education level has been previously associated with social cognitive processes (67) , to the best of our knowledge it has not been previously associated with the domain of social functioning dealing with interactions with relatives, friends and other significant people (58, 68) . However, premorbid IQ (58) and neurocognitive processes (68, 69) have been repeatedly associated with a broader domain profiles of social functioning in the real world (19, 70) . Since education level may be partly due to both premorbid IQ and neurocognitive performances, the associations found in the present study may reflect association between social functioning and neurocognitive performances. However, considering the positive effect of education on IQ (71), education itself may be directly correlated with social functioning. Thus, education level should be considered as a potential contributing factor in the level of social functioning.
Second, in five independent datasets (ES2, ES3, STAR*D, CATIE and STEP-BD) higher professional/work status has been associated with better social functioning, also when weighting for psychopathological severity. Consistently, in three dataset (STEP-BD, CATIE and ES3) this association was confirmed also in the remitted sub-sample (Table 2) . Overall, unemployed patients showed a greater social dysfunction compared to the others. Despite this association could be explained by the consequent lower financial availability of these patients for social leisure activities, also the kind of job seems to play a role. Indeed, among the employed patients, low rank employees showed a greater social dysfunction compared to patients that are self-employed or that hold highrank jobs (e.g., managers). It could be hypothesized that both financial availability and work ing time (or its flexibility) play a relevant role in the modulation of social functioning (see for example (72) ). On the other hand, pre-existing social dysfunction may cause employment barriers, limiting the possibility to achieve better job positions (e.g., (73) ). Furthermore, in two independent datasets (STAR*D and CATIE) to be married has been associated with lower social dysfunction. This result supports a role of a co-habitant partner in sustaining social functioning and quality of life overall, as reported by previous studies (e.g. (74, 75) ). Obviously, this finding may also reflect that patients with higher social functioning could more easily find and maintain a relationship with a partner.
Third, age was found associated with social dysfunction in three datasets (ES1, CATIE and STAR*D) with younger patients showing higher degree of social dysfunction in mood disorder samples also when weighting for psychopathological severity. In the ES1 dataset this association was confirmed also in the remitted sub-sample (Table 2) . Although this result may seem counterintuitive, we suggest that earlier pathophysiological processes may had greatly impacted on social functioning (76) whose normal profile is general more articulated than later in life (77) . On the other hand, in CATIE older age was associated with greater social dysfunction. This could be explained by the natural course of SCZ, which is often characterized by a progressive predominance of negative symptoms in older age (e.g. (78, 79) ).
Fourth, some measures of physical health were found associated with social functioning, with higher social dysfunction associated with higher Body Mass Index (BMI) in three datasets (ES2, ES3, and STEP-BD), smoking habit in two datasets (ES2 and ES3) and medical co-morbidities in STEP-BD dataset, also when weighting for psychopathology severity (see Table 2 ). Despite medical co-morbidities and overweight/obesity may intuitively impact on social functioning (80) (81) (82) , it has also been demonstrated that social dysfunction impacts negatively on global health (1), overweight/obesity (83) and smoking habit (84) . Despite smoking is common in patients affected by psychiatric disorders (85) , the relationship between smoking and psychopathology is still not clear (86, 87) . Nonetheless, it could be hypothesized that social dysfunction may contribute to maintain this habit through the lack of social support, which is a factor contributing to successful smoking cessation (e.g. (88) ). Moreover, obesity seems to impact also on some neurocognitive processes (e.g., (89) ) that may be involved also in the social brain functioning (e.g., attention and working memory) (3, 90) . Therefore, the associations found in our study were consistent with literature data, although the casual relationships between social dysfunction and both health and dangerous habit are still to be elucidated in detail.
Finally, as initially mentioned, we found that psychopathology severity modulates social functioning in all the investigated datasets. This is not surprising, taking into account that social dysfunction has been recognized as a relevant component of both MDD and SCZ clinical severity J o u r n a l P r e -p r o o f and it is listed among their DSM-V diagnostic criteria (91). Nonetheless, the variance of social dysfunction indicators explained by psychopathological severity ranged from 12% to 29.2% in our samples, suggesting that the impact of symptoms on social functioning is significant but in some measures limited. When pooling both psychopathological severity and socio-demographic factors described above in a unified model, the variance of social functioning explained increased to 15-47%. Our results are consistent with previous literature, where only a percentage of real-world social functioning was explained by complex models that included various measures of symptoms, cognition, social cognition, and socio-demographic data (19, 69, 70) . Therefore, although a number of psychopathological, cognitive, and socio-demographic factors may modulate social functioning, other elements, that still need to be identified, likely play a relevant role in causing social dysfunction (92) (93) (94) . Thus, further studies are needed to investigate the other determinants of social functioning in both health subjects and neuropsychiatric patients (22, 95) . Clearly, these studies should carefully consider the factors already associated with social functioning in order to weight their effects, which could mask other associations (3).
A specific attention deserves the association between social functioning and suicide risk that was found in four datasets (ES1, ES2, STAR*D, and STEP-BD), which persists in two datasets (ES1 and STAR*D) also when weighting for psychopathological severity. Although a causal relationship cannot be derived from cross-sectional studies, our result underline the higher risk of suicide in patients with relevant social dysfunction, as already reported in literature (96) . Finally, in two dataset (ES1 and ES2) social dysfunction was associated with both benzodiazepines and antipsychotic co-treatments. Accordingly with literature data (97, 98) , it could be hypothesized that these drugs modulate social functioning, probably through their sedative and extra-pyramidal side effects.
Strengths and limitations of the study
Several limitations are present in our study. Despite the inclusion of 6826 patients affected by MDD, BD and SCZ from four different independent databases, most of the findings reported in the present work will require further studies to confirm the conclusions we proposed. For example, further studies are needed to better define (a) the role of education as critical moderator for social functioning, (b) the role of psychopathological, cognitive, and socio-demographic factors on social dysfunction in MDD, BD and SCZ patients, (c) the relevance of emotional biases in self-assessment of social functioning in MDD, (d) the more marked effects observed in younger age in mood disorders, probably reflecting a different age-dependent normal social functioning and a stronger impact of psychiatric disorders in adolescents. Recently, an example of this kind of studies has been developed: the PRISM project. PRISM is a European founded project that aim to investigate the determinants of social functioning across different neuropsychiatric disorders, applying a deep phenotyping which allows to assess several biological parameters, together with real-life indicators of social functioning and with a careful assessment of possible socio-demographic and psychopathological confounders (95, 99) . We identified other limitations. First, our analyses were cross-sectional, thereby not allowing causal inferences that require longitudinal observations, as previously underlined. Second, the use of derived and operationalized indicator of social dysfunction could be questionable, since post-hoc and not directly validated for the purpose. Third, since they were derived from different scales developed for different purposes, the comparability across the different indicator of social dysfunction is limited. Nonetheless, all the items selected J o u r n a l P r e -p r o o f from the different instruments assess the interactions with relatives, friends and other significant people, allowing a certain degree of comparison. Furthermore, the instruments selected are often self-reported and validation with objective outcomes (i.e. number of friends, contacts per day, social activities, etc.) of social functioning are lacking in the most part of datasets investigated. However, as stated above, also clinician-rated assessment of social functioning (e.g. QOLS "Interpersonal relations" category) may be affected by bias due to the subjective nature of the assessment. Fourth, these indicators were restricted to assess social interaction with friends, relatives and significant people, excluding work/school attendance and not addressing all the other aspects of social functions. Fifth, the use of different social dysfunction indicators across the samples limits the possibility of comparison between diagnoses. Sixth, we perform exploratory analysis on remitted patients only in four datasets, since for two datasets (STAR*D and GSRD ES2) these patients were not available. Further, as stated above, the remission criteria used for the SCZ sample (CATIE), may be questionable, since they are based on the total score of PANSS, possibly leading to a selection of a sub-sample of patients with predominant residual negative symptoms, rather than remitted patients. Finally, since our analyses were all hypothesis-driven and performed in 6 different datasets, we decided to not apply any statistical correction, setting the statistical significance at the standard level of p<0.05. We are aware that our choice may increase the risk of false positive findings, but the comparison of results across different dataset mitigates this possibility.
Conclusion
In conclusion, this study demonstrated that a significant percentage patients affected by MDD, BD and SCZ show relevant social dysfunction. Social dysfunction is importantly related to but not completely explained by psychopathological severity since in some patients it persists during remission. Socio-demographic factors such as age, education level, professional work/status, marital status, medical co-morbidities, and smoking are associated with social functioning and should be taken into account in further studies investigating social dysfunction.
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